Newspaper Archive of
Heritage Florida Jewish News
Fern Park , Florida
Lyft
June 30, 2017     Heritage Florida Jewish News
PAGE 18     (18 of 80 available)        PREVIOUS     NEXT      Full Size Image
 
PAGE 18     (18 of 80 available)        PREVIOUS     NEXT      Full Size Image
June 30, 2017
 

Newspaper Archive of Heritage Florida Jewish News produced by SmallTownPapers, Inc.
Website © 2019. All content copyrighted. Copyright Information.     Terms Of Use.     Request Content Removal.




PAGE 2B HERITAGE FLORIDA JEWISH NEWS, JUNE 30, 2017 a win Staff at Nutrino pick up their award for the Biomed Startup of the Year competition. By Nicky Blackburn Israeli startup companies Betalin Therapeutics, Nutrino Health, and E-Shunt have won the first Biomed Startup of the Year competition, which was held by the Israel Innovation Authority at MIXii Biomed 2017 in Tel Aviv. Forty-five startups took part in this year's biomed ex- hibition, which was held at the David InterContinental, and of these 10 were selected as "Biomed startup of the year" finalists by a team of experts. In the medical devices category, the winner was E- Shunt, which has developed an implant for people suffer- ing from glaucoma, a disease that causes intraocular pres- sure to rise to the point where it can damage eyesight and even cause blindness. The implant, which uses chemical engineering tech- nology and synthetic biology, channels the pressure deeper into the eye socket, releasing pressure on the optic nerve and stopping the progress of the disease. The simple implant process takes less than 10 minutes, considerably shorter than existing glau- coma treatments, and can be carried out by ophthalmolo- gists who are not glaucoma specialists. Artificial pancreas compa- ny Betalin Therapeutics was announced the winner in the category of pharmaceuticals. The company has developed an artificial pancreas that can detect blood-sugar levels. The pancreas is prepared in a lab using cells from clean lung tissue, onto which healthy pancreatic cells from a donor are implanted. These cells regenerate the body's internal insulin, producing capability in accordance with the sugar level in the blood. Nutrino Health, another company that specializes in diabetes, won in the category of digital healthcare. Using de- velopments from the world of big data, the company has de- veloped a digital signature of food stuffs a "food print"-- which is individualized for each person, and makes use of data collected from medical devices, wearables, activity sensors and other biological markers. According to this personal digital signature, and tak- ing into account additional personal parameters, like allergies, food preferences and more, the system offers the patient menus and foods specially adapted to them, either at home or when eat- ing out. The system helps diabetics understand how food affects the management of glucose levels in the blood, enabling them to live a healthier life. "The companies that won signal Israel's future in the rapidly developing life sci- ence ecosystem," said Aharon Aharon, CEO of the Israel Innovation Authority and a judge for the competition. Other competition judges included Dr. Talia Ben-Neria, head of the Life Sciences Department at the Israel In- novation Authority; Tzachi Schnarch, Deputy CEO of Technology and Director of the Technological Array at the Israel Innovation Authority; and Dr. lrit Yaniv from the Israel Advanced Technology Industries (IATI). The focus of this year's MIXiii Biomed conference. the 16th annual event, was ag- ing. Speakers from all over the world addressed issues includ- ing longevity and quality of life, precision medicine, per- sonalized diagnosis, the use of robotics and digital health solutions for the elderly, and age-related diseases. "The startup competition of the MIXiii Biomed 2017 serves.., as a springboard for compaoies seeking to break into commercial markets and to gain exposure among each other in the hope that col- laborative efforts may create solutions for the benefit of humanity," said Ruti Alon, CEO and founder of Medstrada and co-chairperson of MIXiii Biomed. O By Daniel T. Layish M.D., F.A.C.P., F.C.C.P., F.A.A.S.M. Cigarette smoking is the leading preventable cause of mortality. When smokers stop smoking, they reduce the risk of developing (and dying from) tobacco-related dis- eases. According to surveys, approximately 70 percent of smokers want to quit smok- ing and over 40 percent of smokers have tried to quit smoking within the past 12 months. However, less than 7 percent of smokers who make an unassisted attempt to quit smoking remain abstinent after 12 months. Currently, it appears that behavioral counseling com- bined with pharmacotherapy will produce the best results in smoking cessation rates. Nic- otine is a potent psychoactive drug that causes both physical dependence and tolerance. The nicotine withdrawal syndrome can include symp- toms of insomnia, irritability, anxiety, difficulty concentrat- ing, restlessness, increased appetite/weight gain as well as dysphoric mood. It is impor- tant for smokers to know what to expect during a smoking cessation attempt and how to respond if these symptoms occur. Certain situations can increase the risk of relapse, such as having other smokers in the household (or at the work place) or getting into stressful situations. Smoking is also often associated with alcohol use. Many smokers will relapse and wind up making several attempts to quit smoking be- fore they ultimately achieve success. It is therefore im- portant to remember not to be too hard on yourself if your attempt to quit smoking is not successful, but to try to learn from each quit attempt. The average weight gain for people who quit smok- ing is 2-5 pounds in the first two weeks followed by an additional 4-7 pounds over the next four to five months. However, studies have shown that the benefits of smoking cessation outweigh the risk of this degree of weight gain. It is helpful to identify a "quit date." Typically, the quit date should be within two weeks of the decision to attempt to quit smoking. Low tar and low nicotine cigarettes are not recommendedsince they have not been showl to be safer than standard cigarettes or to help with smoking essa- tion. It is helpful for smokers to notify their family, friends and co- workers about their plans to quit and ask for their support. Nicotine replacement ther- apies can be used in combina- tion. For example, nicotine patch can provide a constant low level of nicotine and can be used in conjunction with nicotine gum as needed for breakthrough cravings. Other options for break- .through treatment include a nicotine spray, inhaler and lozenge. The nicotine patch dose should be titrated to the patient's nicotine use. pi- cally, the 7 mg patch will be recommended for somebody who smokes a half pack of cigarettes per day, a 14 mg patch will be recommended for somebody who smokes a pack of cigarettes per day, and acla of Mid-Florida Jeffrey Beattie, D.M.D. Bob Garfinkel, D.M.D. Charles McNamara, D.M.D. Louis Payor, D.D.S. www.ofsmidfl .com Wisdom Teeth, Sedation Dental Implants Winter Park (407) 644-0224 I.,ongwoo, 1o (407) 774-3399 Orlando (407) 843-1670 a 21 mg patch will be recom- mended for somebody who smokes one-and-a-half pack of cigarettes per day or more. The nicotine patch dose can then be tapered over time. Chantix (also called varenicline) is a prescription medication that is very helpful inachieving smoking cessation. The dose is typically 0.5 mg once a day for three days then 0.5 mg twice a day for four days, followed by I mg twice a day, starting at day seven. If a smoker is not able to tolerate the full dose of Chantix, they can decrease to the highest dose that they can tolerate without side effects, Typically, it is recommended to stop smoking one week after start- ing therapy with Chantix. Chantix can be continued on a long-term basis if needed, but typically it is only needed for about 12-24 weeks. Common side effects of Chantix include nausea and abnormal dreams. For most patients, the nausea is tolerable. At one point, there was some concern the Chantix was associated with depres- sion and suicidal ideation. However, recent studies have determined that this is not the case. Another pharmacologic option to help with smoking cessation is Wellbutrin. Well- butrin is an antidepressant that can also be used to help with smoking cessation. It can be used in smokers who are not depressed. Wellbutrin should not be used in people who have epilepsy or a sei- zure disorder. Wellbutrin therapy can be combined recommended for individuals with a history of head trauma, anorexia nervosa, or bulimia or excessive alcohol consump- tion. Like Chantix, Wellbutrin therapy should be started one week before the planned "quit date." One technique that can be used to work with your physi- cian to helpwith smoking ces- sation is the "5R technique." This includes: 1) RELEVENCE, which involves understanding why smoking cessation would be particularly relevant to an individual. For example, a history of diabetes and hypertension would increase risk for cardiovascular disease and might make smoking ces- sation especially important. 2) RISK, in which the patient identifies potential negative consequences of continued tobacco use that are particularly meaningful to them. 3) REWARDS of smol ing cessation such as saving money, improved health, im- proved sense of smell/taste, et cetera. 4) ROADBLOCKS: this involves understanding spe- cific concerns about smoking cessation such as withdrawal symptoms, fear of failure, fear of weight gain, enjoyment of tobacco, et cetera. 5) REPETITION, which involves continued discussion with your healthcare provider at every office visit. Potential resources to help smokers quit include: The American Lung Association website (www.lungusa.org); with nicotine replacement www.quitnet.com; www. therapy.Wellbutrincancause ahectobacco.com or the tele- insomnia and dry mouth, phonehotlineatl-800-QUIT- Wellbutrin would also not be NOW. ] Custom Print Marketing lnvi~tions ~ ~ts [ / Digital g- Of~t Printing Brochures ~ Booklets ] I Direct Mail Services ~:n'ms&Le~ I 407-767-7110 I I " . x,._~_ Mention This Ad and Receive 18% Discount _:,z.~ ]